NamPT Inhibitor Compound Structure for Higher Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NamPT inhibitors, such as FK866, while effective in inducing tumor cell death and inhibiting tumor growth, may have limitations in specificity and potential side effects, necessitating the development of novel compounds with improved efficacy and safety profiles for treating NamPT-related diseases.
Innovation Solution
A novel compound of Chemical Formula 1, its isomers, solvates, hydrates, or pharmaceutically acceptable salts, designed to inhibit nicotinamide phosphoribosyl transferase (NamPT) activity, offering a potential therapeutic agent for NamPT-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FK866 is used as a NamPT inhibitor, then tumor cell death and tumor growth inhibition are achieved, but specificity limitations and potential side effects occur
Solution Approach 1:
The patent modifies the chemical structure parameters of existing NamPT inhibitors by introducing specific substituent groups (R1-R6) at defined positions in the molecular framework. This structural parameter optimization enhances binding affinity and selectivity for NamPT while reducing off-target effects, thereby improving the therapeutic index
Solution Approach 2:
The invention creates a composite molecular structure combining multiple functional groups (pyridine ring, phenol, amide, and substituted alkyl chains) into a single optimized molecule. This composite approach allows simultaneous achievement of high NamPT inhibition potency and improved pharmacological profile through carefully designed molecular components
2Duration of action of moving object
If FK866 is used to deplete cellular NAD+, then tumor cell apoptosis is induced, but immediate cytotoxicity is avoided
Solution Approach 1:
The optimized compound achieves partial inhibition of NamPT activity sufficient to deplete NAD+ levels and trigger apoptotic pathways in tumor cells, but avoids excessive inhibition that would cause immediate cytotoxicity. This controlled partial action allows sustained apoptotic effects while maintaining cell membrane integrity and avoiding necrotic damage
3Adaptability or versatility
If NamPT inhibition is used to treat cancer, then tumor growth is inhibited, but efficacy in inflammatory and metabolic disorders is also needed
Solution Approach 1:
The patent designs a universal NamPT inhibitor structure that can effectively treat multiple disease types including cancer, inflammatory disorders, and metabolic diseases. The molecular framework incorporates functional groups that enable broad-spectrum activity against NamPT across different tissue types and pathological conditions, achieving multi-functionality without requiring separate compounds for each indication
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively inhibits NamPT activity, providing a broad spectrum of therapeutic benefits including cancer treatment, inflammatory disorder management, and metabolic disorder regulation, with reduced side effects and improved efficacy compared to existing inhibitors.
Implementation Method 1
a compound binds to the nicotinamide-binding site of NamPT, inhibiting its activity
Data Source
AI summary
The present invention relates to a novel compound for inhibiting nicotinamide phosphoribosyl transferase (NamPT), a composition including the same, and various uses thereof.